Transparenz: Redaktionell erstellt und geprüft.
Veröffentlicht am

Allikad: Mass General Brigham Journali viide: Hadland, S. E., et al. (2025) Buprenorfiinravi kestus ja järgimine noorte seas ja hilisemad tervisetulemused. Pediaatria. DOI: 10.1542/peds.2025-071147. https://publications.aap.org/pediatrics/article-abstract/doi/10.1542/peds.2025-071147/205461/Buprenorphine-Treatment-Duration-and-Adherence

Quellen: Mass General Brigham Journal reference: Hadland, S. E., et al. (2025) Buprenorphine Treatment Duration and Adherence among Youth and Subsequent Health Outcomes. Pediatrics. DOI: 10.1542/peds.2025-071147. https://publications.aap.org/pediatrics/article-abstract/doi/10.1542/peds.2025-071147/205461/Buprenorphine-Treatment-Duration-and-Adherence
Allikad: Mass General Brigham Journali viide: Hadland, S. E., et al. (2025) Buprenorfiinravi kestus ja järgimine noorte seas ja hilisemad tervisetulemused. Pediaatria. DOI: 10.1542/peds.2025-071147. https://publications.aap.org/pediatrics/article-abstract/doi/10.1542/peds.2025-071147/205461/Buprenorphine-Treatment-Duration-and-Adherence


Allikad:

Journal reference:

Hadland, S.E., et al. (2025) Buprenorfiinravi kestus ja järgimine noorte seas ja hilisemad tervisetulemused. Pediaatria. DOI: 10.1542/peds.2025-071147.  https://publications.aap.org/pediatrics/article-abstract/doi/10.1542/peds.2025-071147/205461/Buprenorphine-Treatment-Duration-and-Adherence